2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.084 Richard O' Hara

PP01.084 Richard O' Hara_NACLC23 Abstract

Pdf Summary

The primary analysis of the Phase II INSIGHT 2 study, evaluating the combination of tepotinib and osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC) with MET amplification, has been reported. The study included 128 patients who had progressed on first-line osimertinib. The primary endpoint was objective response rate (ORR) in patients with central fluorescence in situ hybridization (FISH)-confirmed MET amplification. Secondary endpoints included duration of response (DOR), progression-free survival (PFS), and overall survival (OS). The study found that in patients with FISH MET amplification, the ORR was 50%, with a median DOR of 8.5 months and a median PFS of 5.6 months. Similar outcomes were observed in patients with liquid biopsy next-generation sequencing (NGS) MET amplification. The most common treatment-related adverse event was diarrhea. Tepotinib and osimertinib demonstrated durable responses and a manageable safety profile in this patient population, offering a potential oral targeted therapy option for EGFR-mutant NSCLC patients with MET amplification who have progressed on first-line osimertinib. The study was funded by the healthcare business of Merck KGaA.

Keywords

INSIGHT 2 study

tepotinib

osimertinib

EGFR-mutant NSCLC

MET amplification

objective response rate

FISH

liquid biopsy

adverse event

oral targeted therapy